NDAORALTABLETPriority Review
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXZIDE-25 is a fixed-dose oral combination tablet containing hydrochlorothiazide (thiazide diuretic) and triamterene (potassium-sparing diuretic) approved in 1984. It is indicated for hypertension management by combining two diuretics with complementary mechanisms to reduce sodium retention while preserving potassium. The combination works by inhibiting renal sodium reabsorption at different sites of the nephron, providing synergistic antihypertensive effect.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), suggesting brand team focus is on defending market share against generics and newer antihypertensive classes rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAXZIDE-25 offers limited career growth due to its LOE-Approaching status and minimal linked job openings. Positions available are typically focused on defending market share, managing generic transition, and ensuring compliance rather than innovation or market expansion.
Brand ManagerField Sales Representative
Worked on MAXZIDE-25 at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.